The combination of pan-ErbB tyrosine kinase inhibitor CI-1033 and lovastatin: A potential novel therapeutic approach in squamous cell carcinoma of the head and neck
The ErbB family of receptors are key regulators of growth, differentiation, migration and survival of epithelial cells. CI-1033 is an irreversible pan-ErbB tyrosine kinase inhibitor that has the ability to inhibit EGFR function but has shown limited therapeutic efficacy. Lovastatin targets the activ...
| Main Author: | |
|---|---|
| Language: | en |
| Published: |
2011
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10393/20267 |